We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
Date | Subject | Author | Discuss |
---|---|---|---|
08/12/2020 16:27 | Good timing! | gateside | |
08/12/2020 11:38 | Dipped my toe in at 7960p. Luck to all. | philanderer | |
07/12/2020 17:42 | Market report: AstraZeneca was higher, boosting Pharmaceuticals, after Morgan Stanley upgraded its shares from 'equalweight' to 'overweight'. "The rotation out of momentum, sterling strength and deterioration in vaccine sentiment has created a buying opportunity heading into a positive pipeline and earnings risk set-up in 2021," the broker said. Alliance News | philanderer | |
07/12/2020 15:30 | Two leading coronavirus vaccine developers -- Pfizer Inc. and AstraZeneca Plc -- have applied for emergency use authorization in India, according to the Press Trust of India, raising the likelihood that mass inoculation efforts could begin within weeks in the country of 1.3 billion people. | philanderer | |
07/12/2020 10:09 | MORGAN STANLEY RAISES ASTRAZENECA TO 'OVERWEIGHT' ('EQUAL WEIGHT') - PRICE TARGET 9900 (9400) PENCE | philanderer | |
06/12/2020 17:24 | "When will the Oxford vaccine be ready? A date has not yet been set for when or if the Oxford/AstraZeneca vaccine will be approved, but there are hopes it will be confirmed before Christmas, adding a further 100 million doses of the vaccine to the UK total." | bountyhunter | |
04/12/2020 19:31 | clickable version... | bountyhunter | |
04/12/2020 09:46 | hxxps://www.msn.com/ | turvart | |
04/12/2020 09:42 | End sept news | ashwani01 | |
04/12/2020 09:00 | £105 target by Berenberg | demo trader | |
04/12/2020 08:32 | Takes 2 doses. Fairly sure there are more than 20m | bogman1 | |
04/12/2020 08:30 | The UK have ordered 40M doses of the vaccine from Pfizer Clearly it is intended to be the main thrust V Covid-19 | buywell3 | |
03/12/2020 20:53 | Yes more data is needed,Astra is working on that.There's unlikely to be any approval of the Astra drug in the US until January at the earliest since Astra won't seek a submission before it has completed further trials. | steeplejack | |
03/12/2020 18:57 | Circa £76.66 is the recent low, might be worth a look in that area. | essentialinvestor | |
03/12/2020 18:51 | I feel that it will in UK, more vaccine doses are needed to meet Government timescales. All trial results are well above the 50% benchmark. | bountyhunter | |
03/12/2020 17:25 | I feel in US Astra won't get the ok, more data needed. | montyhedge | |
03/12/2020 16:05 | logistics favours an Astra style drug if it is as effective as other vaccines.Johnson & Johnson are working on a vaccine with results expected in January. Not that i'm a great devotee of charts but just now the RSI suggests Astra is very oversold. | steeplejack | |
03/12/2020 16:02 | My AZN are certainly not for sale. | gateside | |
03/12/2020 15:40 | This is FX imv. | essentialinvestor | |
03/12/2020 15:40 | The problem is if the Yank Vaccine works well why change and | buywell3 | |
03/12/2020 15:33 | I agree Ash, the MMs are probably anticipating a rise when the vaccine is finally approved for emergency use. We can't keep paying a fortune for the US vaccines plus the huge extra costs for distribution and administering. Also there won't be enough doses of those in the time frame the Government have been promoting. | bountyhunter | |
03/12/2020 15:32 | “The shot developed by Oxford and AstraZeneca works like a more tradi-tional vaccine, introducing a weakened virus, in this case one found in chim-panzees, into the body to trigger immunity. It showed an efficacy range of 62% to 90%, depending on the dosage.”Wall St Journal 3 Dec In the U.K.,the Astra drug test results have been well received but in the US it is generally regarded that results fell short of other competing vaccines.This might have impacted sentiment at the same time as sterling strength has weakened off overseas traders and sector rotation has seen switching out of Covid defensives into recovery plays. | steeplejack |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions